Crain’s Detroit Business News Names Immunolight LLC Most Innovative
Company of 2016

Immunolight LLC, a biomedical firm leading the way in technologies that transform energy sources such as low dose X-ray and convert them into energy that is capable of activating a natural compound called psoralen when exposed to UV light, has been named Crain’s Detroit Business News most innovative company for 2016.

X-Ray Psoralen Activated Cancer Therapy
This work investigates X-PACT (X-ray Psoralen Activated Cancer Therapy): a new approach for the treatment of solid cancer. X-PACT utilizes psoralen, a potent anti-cancer therapeutic with current application to proliferative disease and extracorporeal photopheresis (ECP) of cutaneous T Cell Lymphoma. An immunogenic role for light-activated psoralen has been reported, contributing to long-term clinical responses.

Duke Doctors, NCSU Team Up Against Cancer
Eliza, a 13-year old Labrador retriever from Charlotte, is a four-legged miracle. Almost a year and a half ago, her cancer was essentially cured during a clinical trial at N.C. State University’s vet school.Now Eliza and other canine patients might teach researchers something about cancer in their two-legged friends. The Duke Cancer Institute and NCSU’s College of Veterinary Medicine have formed the Consortium for Canine Comparative Oncology, or C3O for short.

Now Recruiting: Immunolight Therapy for Canine Cancer
With the support of the Immunolight team, doctors in the department of Radiation Oncology at NC State’s College of Veterinary medicine are working with researchers at Duke University’s School of Medicine to develop Immunolight therapy. This innovative therapy offers a promising new approach to treating cancer in dogs. > Read More

Cancer SOS Radio: Joni Aldrich Interviews Harold Walder on Immunolight
Co-hosts Joni Aldrich and Dr. Peter Hofland interview Harold Walder, President of Immunolight, on the groundbreaking cancer research and treatment that he and a team of scientists at Duke University Medical Center have been conducting over the past seven years.

Leland Man Behind New Discovery to Aid Breast Cancer Fight
Leland resident Harold Walder and his Durham-based research company, Immunolight, have developed a groundbreaking approach to treating cancer. Walder and a team of scientists at Duke University Medical Center have demonstrated that a compound called psorlen – which occurs naturally in broccoli and figs – was shown to shrink breast cancer tumors in mice when activated by ultraviolet (UV) light. > Read More

New Psoralen Mechanism of Action Discovered That Attacks Breast Cancer Cells
Durham, NC – Immunolight LLC, an emerging leader in the development of a breakthrough platform technology leveraging the latest advances in energy transfer, has announced research about a new mode of action utilizing psoralen, a naturally occurring compound found in broccoli and figs, that may shed new light on the fight against cancer.
For decades, psoralen has been used to treat skin disorders, cancer and autoimmune disease. The compound is inert until activated by UV light, after which it has been shown to interfere with the DNA of a cell and prevent it from replicating. > Read More Natural Compound Attacks HER2 Positive Breast Cancer Cells
DURHAM, N.C. – A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.
The compound is called psoralen, a natural component found in foods such as figs and celery, and researchers have long understood that it that works by disrupting DNA replication and causing cell death when activated by an energy source such as UV light. > Read More

PLOS ONE: Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis
Photo-activation of psoralen with UVA irradiation, referred to as PUVA, is used in the treatment of proliferative skin disorders. The anti-proliferative effects of PUVA have been largely attributed to psoralen intercalation of DNA, which upon UV treatment, triggers the formation of interstrand DNA crosslinks (ICL) that inhibit transcription and DNA replication. Here, we show that PUVA exerts antitumor effects in models of human breast cancer that overexpress the ErbB2 receptor tyrosine kinase oncogene, through a new mechanism. > Read More

An Emerging Technology May Allow Adhesives in Opaque Substrates to be Cured by UV or Visible Light
Adhesives and coatings cured by ultraviolet (UV) or visible light have become valuable tools in modern-day assembly operations, particularly in high-technology industries such as electronics and medical devices. Most UV adhesives are based on free radical polymerization systems with acrylate or methacrylate monomers, although other systems such as cationically cured cycloaliphatic epoxies, vinyl ethers, and oxetanes are known. > Read More

Activity of Psoralen-Functionalized Nanoscintillators against Cancer Cells upon X-ray Excitation
We report development of a nanoparticle-based, X-ray-activated anticancer “nanodrug” composed of yttrium oxide (Y2O3) nanoscintillators, a fragment of the HIV-1 TAT peptide, and psoralen. In this formulation, X-ray radiation is absorbed by the Y2O3 nanoscintillators, which then emit UVA light. Absorption of UVA photons by nanoparticle-tethered psoralen has the potential to cross-link adenine and thymine residues in DNA. UVA-induced cross-linking by free psoralen upon activation with UVA light has previously been shown to cause apoptosis in vitro and an immunogenic response in vivo. > Read More